Global HIV Vaccine Enterprise

AIM: To share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.

Established in 2003, the Global HIV Vaccine Enterprise became a programme of the IAS in 2018.

Several vaccine and biologics efficacy trials are now complete, and these have sharpened the Enterprise's focus on preparing the field for future clinical studies towards a safe and globally efficient HIV vaccine.

This is a unique and exciting moment for the HIV vaccine development field. The Enterprise’s strategic plan for 2018-2023, which is supported by its advisory group, highlights its commitment to:

  • Propel the vaccine pipeline by strengthening strategies that align, amplify and accelerate development of candidate vaccines.
  • Prepare for clinical trial outcomes by tackling priorities essential to clarifying the roadmap for future access to a vaccine.
  • Expand resources and engagement by enlisting a diverse community of partners to support and contribute to the field.

For more information, visit